EBViously, a spin-off from Helmholtz Munich (HMGU), is led by world-leading experts in Epstein-Barr virus biology, genetics, and immunity and was founded to develop a safe and highly effective preventive vaccine against a range of diseases caused by Epstein-Barr virus (EBV), including infectious mononucleosis, various cancers, immune disorders, and multiple sclerosis, and various cancers. EBViously will present its approach and technology at the World Vaccine Congress 2023 (April 4-6, 2023) in Washington, DC, USA.